Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has announced definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of shares. The combined gross proceeds are expected to be approximately $2.9 million, providing the company with additional capital to support its ongoing operations and strategic initiatives.
Under the terms of the agreements, the common shares are priced at $0.795 per share, while the warrants are priced at $0.005 per warrant. Each warrant carries an exercise price of $0.84 per share, offering the investor the opportunity to acquire additional shares at a slight premium to the offering price. The transactions are anticipated to close on or about August 14, 2026, subject to customary closing conditions.
Dyadic intends to use the net proceeds from these offerings, along with its existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. This infusion of capital is expected to strengthen the company's financial position and support its efforts in developing and commercializing its proprietary protein production platforms.
The company, through its Dyadic Applied BioSolutions division, focuses on creating scalable, non-animal protein production systems to address growing demand across the life sciences, food and nutrition, and bio-industrial markets. Its proprietary Dapibus™ and C1 expression systems are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins, which can help customers develop more efficient and sustainable products.
Aegis Capital Corp. is serving as the exclusive placement agent for the offerings. The company has not provided additional details on how the funds will be specifically allocated, but the announcement signals continued investor interest in Dyadic's technology and market potential.
This capital raise comes at a time when the biotechnology sector is seeing increased demand for sustainable and scalable production methods. Dyadic's non-animal platforms could play a significant role in meeting these needs, and the additional funding may accelerate the company's research and development efforts, as well as its commercialization strategies.
For more information about the offerings, interested parties can refer to the full press release at https://ibn.fm/od7FJ. Details about Dyadic International and its technologies are available on the company's website at https://dyadic.com/.
